Methylphenidate improves learning impairments and hyperthermia-induced seizures caused by an Scn1a mutation

Iori Ohmori, Nozomi Kawakami, Sumei Liu, Haijiao Wang, Ikuko Miyazaki, Masato Asanuma, Hiroyuki Michiue, Hideki Matsui, Tomoji Mashimo, Mamoru Oouchida

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Summary Objective Developmental disorders including cognitive deficit, hyperkinetic disorder, and autistic behaviors are frequently comorbid in epileptic patients with SCN1A mutations. However, the mechanisms underlying these developmental disorders are poorly understood and treatments are currently unavailable. Using a rodent model with an Scn1a mutation, we aimed to elucidate the pathophysiologic basis and potential therapeutic treatments for developmental disorders stemming from Scn1a mutations.

Methods We conducted behavioral analyses on rats with the N1417H-Scn1a mutation. With high-performance liquid chromatography, we measured dopamine and its metabolites in the frontal cortex, striatum, nucleus accumbens, and midbrain. Methylphenidate was administered intraperitoneally to examine its effects on developmental disorder-like behaviors and hyperthermia-induced seizures.

Results Behavioral studies revealed that Scn1a-mutant rats had repetitive behavior, hyperactivity, anxiety-like behavior, spatial learning impairments, and motor imbalance. Dopamine levels in the striatum and nucleus accumbens in Scn1a-mutant rats were significantly lower than those in wild-type rats. In Scn1a-mutant rats, methylphenidate, by increasing dopamine levels in the synaptic cleft, improved hyperactivity, anxiety-like behavior, and spatial learning impairments. Surprisingly, methylphenidate also strongly suppressed hyperthermia-induced seizures.

Significance Dysfunction of the mesolimbic dopamine reward pathway may contribute to the hyperactivity and learning impairments in Scn1a-mutant rats. Methylphenidate was effective for treating hyperactivity, learning impairments, and hyperthermia-induced seizures. We propose that methylphenidate treatment may ameliorate not only developmental disorders but also epileptic seizures in patients with SCN1A mutations.

Original languageEnglish
Pages (from-to)1558-1567
Number of pages10
JournalEpilepsia
Volume55
Issue number10
DOIs
Publication statusPublished - Oct 1 2014

Fingerprint

Methylphenidate
Induced Hyperthermia
Seizures
Learning
Mutation
Dopamine
Nucleus Accumbens
Anxiety
Frontal Lobe
Therapeutics
Autistic Disorder
Mesencephalon
Reward
Rodentia
Epilepsy
High Pressure Liquid Chromatography

Keywords

  • Developmental disorders
  • Dopamine
  • Mesolimbic reward pathway
  • Methylphenidate
  • Scn1a

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology
  • Medicine(all)

Cite this

Methylphenidate improves learning impairments and hyperthermia-induced seizures caused by an Scn1a mutation. / Ohmori, Iori; Kawakami, Nozomi; Liu, Sumei; Wang, Haijiao; Miyazaki, Ikuko; Asanuma, Masato; Michiue, Hiroyuki; Matsui, Hideki; Mashimo, Tomoji; Oouchida, Mamoru.

In: Epilepsia, Vol. 55, No. 10, 01.10.2014, p. 1558-1567.

Research output: Contribution to journalArticle

@article{3890d803ea784729ac50e734a8726b8a,
title = "Methylphenidate improves learning impairments and hyperthermia-induced seizures caused by an Scn1a mutation",
abstract = "Summary Objective Developmental disorders including cognitive deficit, hyperkinetic disorder, and autistic behaviors are frequently comorbid in epileptic patients with SCN1A mutations. However, the mechanisms underlying these developmental disorders are poorly understood and treatments are currently unavailable. Using a rodent model with an Scn1a mutation, we aimed to elucidate the pathophysiologic basis and potential therapeutic treatments for developmental disorders stemming from Scn1a mutations.Methods We conducted behavioral analyses on rats with the N1417H-Scn1a mutation. With high-performance liquid chromatography, we measured dopamine and its metabolites in the frontal cortex, striatum, nucleus accumbens, and midbrain. Methylphenidate was administered intraperitoneally to examine its effects on developmental disorder-like behaviors and hyperthermia-induced seizures.Results Behavioral studies revealed that Scn1a-mutant rats had repetitive behavior, hyperactivity, anxiety-like behavior, spatial learning impairments, and motor imbalance. Dopamine levels in the striatum and nucleus accumbens in Scn1a-mutant rats were significantly lower than those in wild-type rats. In Scn1a-mutant rats, methylphenidate, by increasing dopamine levels in the synaptic cleft, improved hyperactivity, anxiety-like behavior, and spatial learning impairments. Surprisingly, methylphenidate also strongly suppressed hyperthermia-induced seizures.Significance Dysfunction of the mesolimbic dopamine reward pathway may contribute to the hyperactivity and learning impairments in Scn1a-mutant rats. Methylphenidate was effective for treating hyperactivity, learning impairments, and hyperthermia-induced seizures. We propose that methylphenidate treatment may ameliorate not only developmental disorders but also epileptic seizures in patients with SCN1A mutations.",
keywords = "Developmental disorders, Dopamine, Mesolimbic reward pathway, Methylphenidate, Scn1a",
author = "Iori Ohmori and Nozomi Kawakami and Sumei Liu and Haijiao Wang and Ikuko Miyazaki and Masato Asanuma and Hiroyuki Michiue and Hideki Matsui and Tomoji Mashimo and Mamoru Oouchida",
year = "2014",
month = "10",
day = "1",
doi = "10.1111/epi.12750",
language = "English",
volume = "55",
pages = "1558--1567",
journal = "Epilepsia",
issn = "0013-9580",
publisher = "Wiley-Blackwell",
number = "10",

}

TY - JOUR

T1 - Methylphenidate improves learning impairments and hyperthermia-induced seizures caused by an Scn1a mutation

AU - Ohmori, Iori

AU - Kawakami, Nozomi

AU - Liu, Sumei

AU - Wang, Haijiao

AU - Miyazaki, Ikuko

AU - Asanuma, Masato

AU - Michiue, Hiroyuki

AU - Matsui, Hideki

AU - Mashimo, Tomoji

AU - Oouchida, Mamoru

PY - 2014/10/1

Y1 - 2014/10/1

N2 - Summary Objective Developmental disorders including cognitive deficit, hyperkinetic disorder, and autistic behaviors are frequently comorbid in epileptic patients with SCN1A mutations. However, the mechanisms underlying these developmental disorders are poorly understood and treatments are currently unavailable. Using a rodent model with an Scn1a mutation, we aimed to elucidate the pathophysiologic basis and potential therapeutic treatments for developmental disorders stemming from Scn1a mutations.Methods We conducted behavioral analyses on rats with the N1417H-Scn1a mutation. With high-performance liquid chromatography, we measured dopamine and its metabolites in the frontal cortex, striatum, nucleus accumbens, and midbrain. Methylphenidate was administered intraperitoneally to examine its effects on developmental disorder-like behaviors and hyperthermia-induced seizures.Results Behavioral studies revealed that Scn1a-mutant rats had repetitive behavior, hyperactivity, anxiety-like behavior, spatial learning impairments, and motor imbalance. Dopamine levels in the striatum and nucleus accumbens in Scn1a-mutant rats were significantly lower than those in wild-type rats. In Scn1a-mutant rats, methylphenidate, by increasing dopamine levels in the synaptic cleft, improved hyperactivity, anxiety-like behavior, and spatial learning impairments. Surprisingly, methylphenidate also strongly suppressed hyperthermia-induced seizures.Significance Dysfunction of the mesolimbic dopamine reward pathway may contribute to the hyperactivity and learning impairments in Scn1a-mutant rats. Methylphenidate was effective for treating hyperactivity, learning impairments, and hyperthermia-induced seizures. We propose that methylphenidate treatment may ameliorate not only developmental disorders but also epileptic seizures in patients with SCN1A mutations.

AB - Summary Objective Developmental disorders including cognitive deficit, hyperkinetic disorder, and autistic behaviors are frequently comorbid in epileptic patients with SCN1A mutations. However, the mechanisms underlying these developmental disorders are poorly understood and treatments are currently unavailable. Using a rodent model with an Scn1a mutation, we aimed to elucidate the pathophysiologic basis and potential therapeutic treatments for developmental disorders stemming from Scn1a mutations.Methods We conducted behavioral analyses on rats with the N1417H-Scn1a mutation. With high-performance liquid chromatography, we measured dopamine and its metabolites in the frontal cortex, striatum, nucleus accumbens, and midbrain. Methylphenidate was administered intraperitoneally to examine its effects on developmental disorder-like behaviors and hyperthermia-induced seizures.Results Behavioral studies revealed that Scn1a-mutant rats had repetitive behavior, hyperactivity, anxiety-like behavior, spatial learning impairments, and motor imbalance. Dopamine levels in the striatum and nucleus accumbens in Scn1a-mutant rats were significantly lower than those in wild-type rats. In Scn1a-mutant rats, methylphenidate, by increasing dopamine levels in the synaptic cleft, improved hyperactivity, anxiety-like behavior, and spatial learning impairments. Surprisingly, methylphenidate also strongly suppressed hyperthermia-induced seizures.Significance Dysfunction of the mesolimbic dopamine reward pathway may contribute to the hyperactivity and learning impairments in Scn1a-mutant rats. Methylphenidate was effective for treating hyperactivity, learning impairments, and hyperthermia-induced seizures. We propose that methylphenidate treatment may ameliorate not only developmental disorders but also epileptic seizures in patients with SCN1A mutations.

KW - Developmental disorders

KW - Dopamine

KW - Mesolimbic reward pathway

KW - Methylphenidate

KW - Scn1a

UR - http://www.scopus.com/inward/record.url?scp=84911462983&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84911462983&partnerID=8YFLogxK

U2 - 10.1111/epi.12750

DO - 10.1111/epi.12750

M3 - Article

C2 - 25154505

AN - SCOPUS:84911462983

VL - 55

SP - 1558

EP - 1567

JO - Epilepsia

JF - Epilepsia

SN - 0013-9580

IS - 10

ER -